var data={"title":"Sildenafil: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Sildenafil: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6951?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=sildenafil-patient-drug-information\" class=\"drug drug_patient\">see &quot;Sildenafil: Patient drug information&quot;</a> and <a href=\"topic.htm?path=sildenafil-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Sildenafil: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F220995\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Revatio;</li>\n      <li>Viagra</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F220996\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Revatio;</li>\n      <li>Viagra</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F221028\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Phosphodiesterase-5 Enzyme Inhibitor</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F221000\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Erectile dysfunction</b> (Viagra): Oral: Usual dose: 50 mg once daily 1 hour (range: 30 minutes to 4 hours) before sexual activity as needed; dosing range: 25 to 100 mg once daily; maximum dose: 100 mg once daily.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Pulmonary arterial hypertension (PAH)</b> (Revatio):</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IV: 2.5 mg or 10 mg 3 times daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Manufacturer&rsquo;s labeling: 5 mg or 20 mg 3 times daily, administered 4 to 6 hours apart; maximum dose: 20 mg 3 times daily</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Alternate recommendations: 20 mg to 40 mg 3 times daily; may increase to a maximum of 80 mg 3 times daily in patients who do not achieve an adequate response (ACCP [Taichman 2014]; Gali&egrave; 2005)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Raynaud phenomenon (off-label use):</b> Oral: 50 mg twice daily. Clinical trials were up to 4 weeks. (Fries 2005; Roustit 2013)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Dosage considerations for patients stable on alpha-blockers:</b> Viagra: Initial: 25 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosage adjustment for concomitant use of potent CYP34A inhibitors:</b> Viagra:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Strong CYP3A inhibitors (eg, itraconazole, ketoconazole, saquinavir) or erythromycin: Starting dose of 25 mg should be considered</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Protease inhibitors: Maximum sildenafil dose: 25 mg every 48 hours</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F221001\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Elderly &gt;65 years: Use with caution.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Erectile dysfunction (Viagra): Oral: Starting dose of 25 mg should be considered.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">PAH (Revatio): Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F221002\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">CrCl &ge;30 mL/minute: No dosage adjustment necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">CrCl &lt;30 mL/minute:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">Revatio: No dosage adjustment  necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">Viagra: Starting dose of 25 mg should be considered.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F221003\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mild to moderate impairment (Child-Pugh classes A and B):</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Revatio: No dosage adjustment  necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Viagra: Starting dose of 25 mg should be considered.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Severe impairment (Child-Pugh class C):</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Revatio: There are no dosage adjustments provided in the manufacturer&rsquo;s labeling (has not been studied).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Viagra: Starting dose of 25 mg should be considered.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F220969\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Revatio: 10 mg/12.5 mL (12.5 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 10 mg/12.5 mL (12.5 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Suspension Reconstituted, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Revatio: 10 mg/mL (112 mL) [contains sodium benzoate]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Revatio: 20 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Viagra: 25 mg, 50 mg, 100 mg [contains fd&amp;c blue #2 aluminum lake]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 20 mg, 25 mg, 50 mg, 100 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F220955\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">May be product dependent</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F220971\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Revatio: Administer doses at least 4 to 6 hours apart with or without food. Shake oral suspension well for &ge;10 seconds before administering dose; do not mix with any other medication or additional flavoring agent.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Viagra: Administer with or without food 30 minutes to 4 hours before sexual activity</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IV: Revatio: Administer as an IV bolus.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F220970\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">\n      <b>Erectile dysfunction:</b> Viagra: Treatment of erectile dysfunction (ED)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Pulmonary arterial hypertension:</b> Revatio: Treatment of pulmonary arterial hypertension (PAH) (WHO Group I; efficacy established predominately in patients with WHO/NYHA functional class II and III) in adults to improve exercise ability and delay clinical worsening.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25744905\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Achalasia/Esophageal motility disorders; Persistent pulmonary hypertension after recent left ventricular assist device placement; Raynaud phenomenon; Sexual dysfunction (antidepressant/antipsychotic-induced)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F221036\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Revatio may be confused with ReVia, Revonto</p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Sildenafil may be confused with silodosin, tadalafil, vardenafil</p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Viagra may be confused with Allegra, Vaniqa</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F220962\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Based upon normal doses for either indication or route. (Adverse effects such as flushing, diarrhea, myalgia, and visual disturbances may be increased with adult doses &gt;100 mg/24 hours.)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">&gt;10%: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cardiovascular: Flushing (10% to 19%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Central nervous system: Headache (16% to 46%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Gastrointestinal: Dyspepsia (3% to 17%; dose-related)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Ophthalmic: Visual disturbance (2% to 11%; including vision color changes, blurred vision, and photophobia; dose-related)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Respiratory: Epistaxis (9% to 13%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">2% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Central nervous system: Insomnia (&le;7%), dizziness (2% to 4%), paresthesia (&le;3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Dermatologic: Erythema (6%), skin rash (1% to 3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Gastrointestinal: Diarrhea (3% to 9%), gastritis (&le;3%), nausea (2% to 3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Genitourinary: Urinary tract infection (3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Hepatic: Increased liver enzymes (2% to 10%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Neuromuscular &amp; skeletal: Myalgia (2% to 7%), back pain (3% to 4%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Respiratory: Nasal congestion (4% to 9%), exacerbation of dyspnea (&le;7%), nasal congestion (4%), rhinitis (4%), sinusitis (3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Miscellaneous: Fever (6%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">&lt;2%, postmarketing, and/or case reports (limited to important or life-threatening): Abdominal pain, abnormal dreams, abnormal hepatic function tests, absent reflexes, accidental injury, amnesia (transient global), anemia, angina pectoris, anorgasmia, anterior chamber eye hemorrhage, anterior ischemic optic neuropathy, anxiety, arthritis, asthma, ataxia, atrioventricular block, auditory impairment, basal cell carcinoma (Loeb 2015), bone pain, breast hypertrophy, bronchitis, burning sensation of eyes, cardiac arrest, cardiac failure, cardiomyopathy, cataract, cerebral hemorrhage, cerebral thrombosis, cerebrovascular hemorrhage, chest pain, chills, colitis, conjunctivitis, contact dermatitis, cystitis, depression, dermal ulcer, diaphoresis, diplopia, drowsiness, dry eye syndrome, dysphagia, ECG abnormality, edema, ejaculatory disorder, esophagitis, exfoliative dermatitis, eye pain, eye redness, facial edema, falling, gastroenteritis, genital edema, gingivitis, glossitis, gout, hearing loss, hematuria, hemorrhage, herpes simplex infection, hyperglycemia, hypernatremia, hypersensitivity reaction, hypertension, hypertonia, hyperuricemia, hypoesthesia, hypoglycemia, hypotension, increased bronchial secretions, increased cough, increased intraocular pressure, increased thirst, ischemic heart disease, leukopenia, laryngitis, malignant melanoma (Li 2014; Loeb 2015), migraine, myasthenia, mydriasis, myocardial infarction, neuralgia, neuropathy, nocturia, orthostatic hypotension, ostealgia, osteoarthritis, otalgia, pain, palpitations, peripheral edema, pharyngitis, photophobia, priapism, prolonged erection, pruritus, pulmonary hemorrhage, rectal hemorrhage, retinal edema, retinal hemorrhage, retinal vascular disease, rupture of tendon, seizure, severe sickle cell crisis (vaso-occlusive crisis in patients with pulmonary hypertension associated with sickle cell disease), shock, skin photosensitivity, stomatitis, subarachnoid hemorrhage, swelling of eye, syncope, synovitis, tachycardia, temporary vision loss, tenosynovitis, tinnitus, transient ischemic attacks, tremor, unstable diabetes, urinary frequency, urinary incontinence, urticaria, ventricular arrhythmia, vertigo, visual field loss, vitreous detachment, vitreous traction, vomiting, weakness, xerostomia</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F220974\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity to sildenafil or any component of the formulation; concurrent use (regularly/intermittently) of organic nitrates in any form (eg, nitroglycerin, isosorbide dinitrate); concomitant use of riociguat (a guanylate cyclase stimulator).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">According to the manufacturers of protease inhibitors  (atazanavir, darunavir, fosamprenavir, indinavir, lopinavir/ritonavir, nelfinavir, ritonavir, saquinavir, tipranavir): Concurrent use with a protease inhibitor regimen when sildenafil is used for pulmonary artery hypertension (eg, Revatio).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling: </i>Additional contraindications (not in US labeling):</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">Viagra: Prior episode of non-arteritic anterior ischemic optic neuropathy (NAION).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">Revatio: Prior episode of non-arteritic anterior ischemic optic neuropathy (NAION); concurrent use with potent CYP3A4 inhibitors (eg, ketoconazole, itraconazole, ritonavir); pulmonary hypertension secondary to sickle cell anemia; severe hepatic impairment; recent history of stroke or MI, or life-threatening arrhythmia; coronary artery disease causing unstable angina; severe hypotension (&lt;90/50 mm Hg) at initiation.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F220959\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Color discrimination: May cause dose-related impairment of color discrimination. Use caution in patients with retinitis pigmentosa; a minority have genetic disorders of retinal phosphodiesterases (no safety information available).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hearing loss: Sudden decrease or loss of hearing has been reported; hearing changes may be accompanied by tinnitus and dizziness. A direct relationship between therapy and hearing loss has not been determined.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity: Hypersensitivity reactions, including rash, urticaria, anaphylactic reaction, and anaphylactic shock, have been reported.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypotension: Decreases in blood pressure may occur due to vasodilator effects; use with caution in patients with left ventricular outflow obstruction (aortic stenosis, hypertrophic obstructive cardiomyopathy), those on antihypertensive therapy, with resting hypotension (BP &lt;90/50 mm Hg), fluid depletion, or autonomic dysfunction; may be more sensitive to hypotensive actions. Patients should be hemodynamically stable prior to initiating therapy at the lowest possible dose. Monitor blood pressure when combining with medications that lower blood pressure. Substantial consumption of ethanol may increase the risk of hypotension and orthostasis. Lower ethanol consumption has not been associated with significant changes in blood pressure or increase in orthostatic symptoms. Have patients avoid or limit ethanol consumption.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Priapism: Painful erection &gt;6 hours in duration has been reported rarely. Educate patient to seek medical assistance for erection lasting &gt;4 hours.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Vision loss: Sudden loss of vision in one or both eyes, including permanent loss of vision, may occur and be a sign of nonarteritic anterior ischemic optic neuropathy (NAION). Risk may be increased with history of vision loss. Other risk factors for NAION include low cup-to-disc ratio (&ldquo;crowded disc&rdquo;), coronary artery disease, diabetes, hypertension, hyperlipidemia, smoking, and &gt;50 years of age. Patients suffering sudden vision loss should discontinue therapy and consult health care provider immediately. A direct relationship between therapy and vision loss has not been determined.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Anatomical penis deformation: Use with caution in patients with anatomical deformation of the penis (angulation, cavernosal fibrosis, or Peyronie disease).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Bleeding disorders: Use with caution in patients with bleeding disorders; safety has not been established. <i>In vitro</i> studies have suggested a decreased effect on platelet aggregation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardiovascular disease: Use with caution in patients with hypotension (&lt;90/50 mm Hg); uncontrolled hypertension (&gt;170/110 mm Hg); life-threatening arrhythmias, stroke or MI within the last 6 months; cardiac failure or coronary artery disease causing unstable angina; safety and efficacy have not been studied in these patients. Use caution in patients with left ventricular outflow obstruction (eg, aortic stenosis). There is a degree of cardiac risk associated with sexual activity; therefore, health care providers should consider the cardiovascular status of their patients prior to initiating any treatment for erectile dysfunction.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Conditions predisposing to priapism: Use with caution in patients who have conditions which may predispose them to priapism (sickle cell anemia, multiple myeloma, leukemia). All patients should be instructed to seek immediate medical attention if erection persists &gt;4 hours.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Use Viagra with caution in patients with hepatic impairment; use lowest starting dose (25 mg).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Peptic ulcer disease: Use with caution in patients with active peptic ulcer disease; safety has not been established.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; PAH: Sudden cessation of sildenafil monotherapy could result in an exacerbation of PAH. Efficacy in adult patients determined through short-term (12-16 week) studies; safety of longer-term use is unclear. A long-term use trial in pediatric patients showed increased mortality in the higher dose groups (20-80 mg [depending upon weight] 3 times/day) after 2 years of use (Barst 2012a; Barst 2012b).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pulmonary veno-occlusive disease: Use in patients with pulmonary veno-occlusive disease (PVOD) is not recommended (has not been studied); if pulmonary edema occurs when treating pulmonary arterial hypertension (PAH), consider the possibility of PVOD.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use Viagra with caution in patients with renal impairment; dose adjustment may be needed; use lowest starting dose (25 mg) in severe dysfunction (CrCl &lt;30 mL/minute).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Sickle cell anemia: Treatment of pulmonary hypertension with sildenafil in this patient population may lead to more hospitalizations for management of vaso-occlusive crises. The effectiveness and safety of sildenafil have not been established in pulmonary hypertension secondary to sickle cell disease.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Nitrates: Use of sildenafil is contraindicated in patients currently taking nitrate preparations. However, when nitrate administration becomes medically necessary, the ACCF/AHA 2013 guidelines on treatment of ST-segment elevation MI and the ACCF/AHA 2012 guidelines on treatment of unstable angina/non ST-segment elevation MI support administration of nitrates only if 24 hours have elapsed after use of sildenafil (ACCF/AHA [Anderson 2013]; ACCF/AHA [O'Gara 2013]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pediatric: Use of Revatio, especially chronic use, is not recommended in children. After 2 years of treatment, increased mortality was seen in a long-term (median treatment exposure: 4.6 years) study at higher doses (20 to 80 mg [depending upon weight] 3 times/day) (Barst 2012a; Barst 2012b).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Elderly: Use with caution; dose adjustment may be required.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Benzyl alcohol and derivatives: Some dosage forms may contain sodium benzoate/benzoic acid; benzoic acid (benzoate) is a metabolite of benzyl alcohol; large amounts of benzyl alcohol (&ge;99 mg/kg/day) have been associated with a potentially fatal toxicity (&ldquo;gasping syndrome&rdquo;) in neonates; the &ldquo;gasping syndrome&rdquo; consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse (AAP [&quot;Inactive&quot; 1997]; CDC 1982); some data suggests that benzoate displaces bilirubin from protein binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol derivative with caution in neonates. See manufacturer's labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Suspension: Oral suspensions may be available in multiple concentrations (commercially available: 10 mg/mL; extemporaneous preparation: 2.5 mg/mL); dosing should be presented in mg of sildenafil; use extra precaution when verifying product formulation and calculation of dose volumes. The 2 mL oral syringe provided by the manufacturer only provides measurements for fixed doses of 5 mg and 20 mg; for patients not receiving either of these fixed doses, an appropriate-size calibrated oral syringe will need to be dispensed.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: In the treatment of erectile dysfunction potential underlying causes of erectile dysfunction should be evaluated prior to initiating sildenafil treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Limitations of use: In the treatment of pulmonary arterial hypertension the addition of sildenafil to bosentan therapy does not result in any beneficial effect on exercise capacity.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F221022\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of CYP1A2 (minor), CYP2C19 (minor), CYP2C9 (minor), CYP2D6 (minor), CYP2E1 (minor), CYP3A4 (major); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential; <b>Inhibits</b> CYP2C9 (weak)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F220964\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9643&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Alcohol (Ethyl): May enhance the hypotensive effect of Phosphodiesterase 5 Inhibitors.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Alpha1-Blockers (Nonselective): Phosphodiesterase 5 Inhibitors may enhance the hypotensive effect of Alpha1-Blockers (Nonselective).  Management: Ensure patient is stable on one agent prior to initiating the other, and always initiate combination using the lowest possible dose of the drug being added. When tadalafil is used for treatment of BPH, concurrent alpha 1-blockers are not recommended.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Alpha1-Blockers (Uroselective): May enhance the hypotensive effect of Phosphodiesterase 5 Inhibitors.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Alprostadil: Phosphodiesterase 5 Inhibitors may enhance the adverse/toxic effect of Alprostadil. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amyl Nitrite: Phosphodiesterase 5 Inhibitors may enhance the vasodilatory effect of Amyl Nitrite. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aprepitant: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Blood Pressure Lowering Agents: Phosphodiesterase 5 Inhibitors may enhance the hypotensive effect of Blood Pressure Lowering Agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Boceprevir: May increase the serum concentration of Sildenafil. Management: Avoid sildenafil when used for treatment of pulmonary arterial hypertension in patients receiving boceprevir.  Sildenafil for erectile dysfunction should be limited to 25 mg every other day with close monitoring for sildenafil toxicity.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bosentan: May decrease the serum concentration of Phosphodiesterase 5 Inhibitors. Phosphodiesterase 5 Inhibitors may increase the serum concentration of Bosentan.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bosentan: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ceritinib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Management: Use of ceritinib with a narrow therapeutic index CYP3A substrate (eg, alfentanil, cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus) should be avoided when possible.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Clarithromycin: May increase the serum concentration of Sildenafil.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Conivaptan: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inducers (Moderate): May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates (High risk with Inducers). Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inhibitors (Moderate): May increase the serum concentration of Sildenafil.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inhibitors (Strong): May increase the serum concentration of Sildenafil. Management: Use of sildenafil for pulmonary hypertension should be avoided with strong CYP3A4 inhibitors.  When used for erectile dysfunction, starting adult dose should be reduced to 25 mg.  Maximum adult dose with ritonavir or cobicistat is 25 mg per 48 hours.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dabrafenib: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Seek alternatives to the CYP3A4 substrate when possible.  If concomitant therapy cannot be avoided, monitor clinical effects of the substrate closely (particularly therapeutic effects).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dapoxetine: May enhance the orthostatic hypotensive effect of Phosphodiesterase 5 Inhibitors.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dasatinib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferasirox: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Enzalutamide: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Concurrent use of enzalutamide with CYP3A4 substrates that have a narrow therapeutic index should be avoided.  Use of enzalutamide and any other CYP3A4 substrate should be performed with caution and close monitoring.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Erythromycin (Systemic): May increase the serum concentration of Sildenafil. Management: For pulmonary arterial hypertension, US label recommends no dose adjustment and Canadian label recommends reducing to 20mg twice/day.  For erectile dysfunction, consider using a lower starting dose of 25mg in patients who are also taking erythromycin.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Etravirine: May decrease the serum concentration of Phosphodiesterase 5 Inhibitors. Management: No empiric dosage adjustments are recommended with concomitant therapy; however, dose of the phosphodiesterase inhibitor may need to be altered based on clinical response.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fluconazole: May increase the serum concentration of Sildenafil.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fosaprepitant: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fusidic Acid (Systemic): May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Grapefruit Juice: May increase the serum concentration of Sildenafil.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Idelalisib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Itraconazole: May increase the serum concentration of Sildenafil. Management: Concurrent itraconazole is not recommended when sildenafil is used for treatment of pulmonary arterial hypertension. If sildenafil is used to treat erectile dysfunction, an initial dose of 25 mg is recommended with concurrent itraconazole.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ketoconazole (Systemic): May increase the serum concentration of Sildenafil. Management: Concurrent ketoconazole is not recommended when sildenafil is used for treatment of pulmonary arterial hypertension. If sildenafil is used to treat erectile dysfunction, an initial dose of 25 mg is recommended with concurrent ketoconazole.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lorcaserin: May enhance the adverse/toxic effect of Phosphodiesterase 5 Inhibitors. Specifically, the risk of developing priapism may be increased.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MiFEPRIStone: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Management: Minimize doses of CYP3A4 substrates, and monitor for increased concentrations/toxicity, during and 2 weeks following treatment with mifepristone. Avoid cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mitotane: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Doses of CYP3A4 substrates may need to be adjusted substantially when used in patients being treated with mitotane.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Molsidomine: May enhance the hypotensive effect of Phosphodiesterase 5 Inhibitors.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nefazodone: May increase the serum concentration of Sildenafil.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Netupitant: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nitroprusside: Phosphodiesterase 5 Inhibitors may enhance the hypotensive effect of Nitroprusside. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Palbociclib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Phosphodiesterase 5 Inhibitors: May enhance the adverse/toxic effect of other Phosphodiesterase 5 Inhibitors.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pitolisant: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Combined use of pitolisant with a CYP3A4 substrate that has a narrow therapeutic index should be avoided. Other CYP3A4 substrates should be monitored more closely when used with pitolisant.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Posaconazole: May increase the serum concentration of Sildenafil. Management: Concurrent posaconazole is not recommended when sildenafil is used for treatment of pulmonary arterial hypertension. If sildenafil is used to treat erectile dysfunction, an initial dose of 25 mg is recommended with concurrent posaconazole.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protease Inhibitors: May increase the serum concentration of Sildenafil. Management: Erectile dysfunction: sildenafil max = 25 mg/48 hrs with ritonavir, atazanavir, or darunavir; starting dose = 25 mg with other protease inhibitors (adult doses).  Contraindicated if sildenafil being used for pulmonary arterial hypertension.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Riociguat: Phosphodiesterase 5 Inhibitors may enhance the hypotensive effect of Riociguat. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sapropterin: May enhance the hypotensive effect of Phosphodiesterase 5 Inhibitors.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Saquinavir: May increase the serum concentration of Sildenafil. Management: Used for PAH: no dose adjustment recommended per US label, Canadian label recommends decrease to 20 mg twice/day. Used for ED: consider a lower starting dose of 25 mg with concurrent saquinavir.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sarilumab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Siltuximab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Simeprevir: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Simeprevir: May increase the serum concentration of Phosphodiesterase 5 Inhibitors.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">St John's Wort: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Stiripentol: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Management: Use of stiripentol with CYP3A4 substrates that are considered to have a narrow therapeutic index should be avoided due to the increased risk for adverse effects and toxicity.  Any CYP3A4 substrate used with stiripentol requires closer monitoring.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Telaprevir: May increase the serum concentration of Sildenafil. Management: Concurrent use of sildenafil for treatment of pulmonary arterial hypertension is contraindicated with telaprevir.  Sildenafil for erectile dysfunction should be limited to 25 mg per 48 hours, with close monitoring for sildenafil toxicity.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Telithromycin: May increase the serum concentration of Sildenafil.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vasodilators (Organic Nitrates): Phosphodiesterase 5 Inhibitors may enhance the vasodilatory effect of Vasodilators (Organic Nitrates). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Voriconazole: May increase the serum concentration of Sildenafil. Management: Concurrent voriconazole is not recommended when sildenafil is used for treatment of pulmonary arterial hypertension. If sildenafil is used to treat erectile dysfunction, an initial dose of 25 mg is recommended with concurrent voriconazole.<i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F220991\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:0em;margin-left:0em;display:inline\">Grapefruit juice may increase serum levels/toxicity of sildenafil. Management: Avoid grapefruit juice. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F220978\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Information related to the use of sildenafil for the treatment of pulmonary arterial hypertension (PAH) in pregnant women is limited (Cartago 2014; Hsu 2011; Wollein 2016). Women with pulmonary arterial hypertension are encouraged to avoid pregnancy (McLaughlin 2009; Taichman 2014). Because sildenafil causes vasodilation in the uterus, it is currently under study for various obstetric uses (Dunn 2016; Dunn 2017; Pels 2017).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16571140\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sildenafil is present in breast milk.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">The excretion of sildenafil and desmethylsildenafil in breast milk was described in a case report following maternal use for the treatment of PAH (Wollein 2016).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9614168\" class=\"block dic drugH1Div\"><span class=\"drugH1\">Dietary Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Avoid grapefruit juice.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14971852\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Monitor blood pressure and pulse when used concurrently with medications that lower blood pressure; monitor for pulmonary edema</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F220958\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">Erectile dysfunction: Does not directly cause penile erections, but affects the response to sexual stimulation. The physiologic mechanism of erection of the penis involves release of nitric oxide (NO) in the corpus cavernosum during sexual stimulation. NO then activates the enzyme guanylate cyclase, which results in increased levels of cyclic guanosine monophosphate (cGMP), producing smooth muscle relaxation and inflow of blood to the corpus cavernosum. Sildenafil enhances the effect of NO by inhibiting phosphodiesterase type 5 (PDE-5), which is responsible for degradation of cGMP in the corpus cavernosum; when sexual stimulation causes local release of NO, inhibition of PDE-5 by sildenafil causes increased levels of cGMP in the corpus cavernosum, resulting in smooth muscle relaxation and inflow of blood to the corpus cavernosum; at recommended doses, it has no effect in the absence of sexual stimulation.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">Pulmonary arterial hypertension (PAH): Inhibits phosphodiesterase type 5 (PDE-5) in smooth muscle of pulmonary vasculature where PDE-5 is responsible for the degradation of cyclic guanosine monophosphate (cGMP). Increased cGMP concentration results in pulmonary vasculature relaxation; vasodilation in the pulmonary bed and the systemic circulation (to a lesser degree) may occur.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F220973\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Onset of action: Erectile dysfunction: ~60 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Peak effect: Decrease blood pressure: Oral: 1 to 2 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Duration: Erectile dysfunction: 2 to 4 hours; Decrease blood pressure: &lt;8 hours </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: Rapid; slower with a high-fat meal; tablet and suspension are bioequivalent </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: Distributes into tissues</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">V<sub>d</sub> total: Neonates: 22.4 L (or 456 L/70 kg) (Mukherjee 2009) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\"> V<sub>dss</sub>: Adults: 105 L</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding, plasma: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Neonates: Sildenafil: 93.9% &plusmn; 2.5%; N-desmethyl metabolite: 92% &plusmn; 3% (Mukherjee 2009) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Adults: Sildenafil and N-desmethyl metabolite: ~96% </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Hepatic via CYP3A4 (major) and CYP2C9 (minor route); major metabolite (UK-103320 or desmethylsildenafil) is formed via N-desmethylation pathway and has 50% of the activity as sildenafil </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Bioavailability: Oral: Mean: 41%; range: 25% to 63%; may be higher in patients with PAH compared to healthy volunteers; <b>Note:</b> A 10 mg dose of the injection is predicted to have an effect equal to a 20 mg oral dose taking into consideration the parent drug and active metabolite </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Sildenafil: Terminal:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Neonates: PNA 1 day: 55.9 hours (Mukherjee 2009)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Neonates: PNA 7 days: 47.7 hours (Mukherjee 2009)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Adults: 4 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Active N-desmethyl metabolite: Terminal:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Neonates: 11.9 hours (Mukherjee 2009) </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Adults: 4 hours </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak: Oral: Fasting: 30 to 120 minutes (median 60 minutes); delayed by 60 minutes with a high-fat meal </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Feces (~80%, as metabolites); urine (~13%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Clearance: Decreased in patients with hepatic cirrhosis or severe renal impairment; clearance may be lower in patients with PAH compared to normal volunteers. Sildenafil clearance in newborns is significantly decreased compared to adults, but approaches adult (allometrically scaled) values by the first week of life (Mukherjee 2009). Clearance of N-desmethyl active metabolite is decreased in patients with severe renal impairment.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F220977\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Revatio Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg/12.5 mL (12.5 mL): $251.24</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Sildenafil Citrate Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg/12.5 mL (12.5 mL): $220.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Suspension (reconstituted)</b> (Revatio Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg/mL (112 mL): $9,883.76</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Revatio Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 mg (90): $5,151.08</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Sildenafil Citrate Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 mg (90): $1,800.26</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">25 mg (30): $1,993.91</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg (30): $1,993.91</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg (30): $1,993.91</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Viagra Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">25 mg (30): $2,424.60</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg (30): $2,424.60</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg (30): $2,424.60</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F220980\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Acmegra (BD);</li>\n      <li>Adegra (BD);</li>\n      <li>Adonix (PH);</li>\n      <li>Amfidor (CZ);</li>\n      <li>Andros (PH);</li>\n      <li>Androz (ET);</li>\n      <li>Aphrodil (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);</li>\n      <li>Avigra (ZW);</li>\n      <li>Avixar (LV);</li>\n      <li>Azulsix (ES);</li>\n      <li>Balcoga (CZ);</li>\n      <li>Blugral (IE);</li>\n      <li>Bultis Film (KR);</li>\n      <li>Canova (ZW);</li>\n      <li>Caprenafil (ID);</li>\n      <li>Cilafil (AT);</li>\n      <li>Cupid (ET, VN);</li>\n      <li>Direktan (AT);</li>\n      <li>Dragul (ES);</li>\n      <li>Ecriten (LV);</li>\n      <li>Edegra (IN, SG);</li>\n      <li>Edyfil (MY);</li>\n      <li>Ejertol (CO);</li>\n      <li>Elonza (MY, TH);</li>\n      <li>Ereccil (PY);</li>\n      <li>Erecstar (EC);</li>\n      <li>Erectol (AR);</li>\n      <li>Erilin (CO);</li>\n      <li>Ernafil (HK, SG);</li>\n      <li>Eromaks (UA);</li>\n      <li>Eroton (BG);</li>\n      <li>Eroxim (CO);</li>\n      <li>Facsid (LK);</li>\n      <li>Fexion (ES);</li>\n      <li>For MR. (KR);</li>\n      <li>Fortera Orally Soluble Film (KR);</li>\n      <li>Freeya (KR);</li>\n      <li>Funcional (EC);</li>\n      <li>Grandipam (CZ);</li>\n      <li>Happigra Gran (KR);</li>\n      <li>Hippigra (HK);</li>\n      <li>Hydenex (PH);</li>\n      <li>Idilico (AT);</li>\n      <li>Immense (BD);</li>\n      <li>Iqnyde (MY);</li>\n      <li>Ivagra (LK);</li>\n      <li>Kamagra (ET, ZW);</li>\n      <li>Katora (CZ);</li>\n      <li>Lekap (TR);</li>\n      <li>Maxigra (HK);</li>\n      <li>Neo-Up (PH);</li>\n      <li>Nipatra (GB);</li>\n      <li>Olvion (RO, SG);</li>\n      <li>Osigra (LK);</li>\n      <li>Pahtension (KR);</li>\n      <li>Palpal Chew Tab (KR);</li>\n      <li>Patrex (SE);</li>\n      <li>Penegra (BF, BJ, CI, ET, GH, GM, GN, IN, KE, LR, MA, ML, MR, MU, MW, NE, NG, PH, SC, SD, SL, SN, TN, TZ, UG, ZM, ZW);</li>\n      <li>Pramil (PY);</li>\n      <li>Pronafil (PH);</li>\n      <li>Pulmolan (AT);</li>\n      <li>Remenafil (SG);</li>\n      <li>Revatio (AT, AU, BB, BE, CH, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HK, HR, HU, IE, IL, IS, IT, JP, KR, LT, LU, LV, MT, MY, NL, NZ, PL, PT, RO, RU, SE, SI, SK, TH, TR, TW);</li>\n      <li>Rigix (PY);</li>\n      <li>Ripol (CL);</li>\n      <li>Sanbenafil (ID);</li>\n      <li>Seregra (ZW);</li>\n      <li>Serivia Gran (KR);</li>\n      <li>Sidegra (TH);</li>\n      <li>Sidena (IE);</li>\n      <li>Silagra (ET);</li>\n      <li>Silatio (TH);</li>\n      <li>Silchemo (AT);</li>\n      <li>Sildefil (AR);</li>\n      <li>Sildegra (SG);</li>\n      <li>Silvie (KR);</li>\n      <li>Supra (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);</li>\n      <li>Syldokad (UA);</li>\n      <li>Tagazepin (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Tigerfil (HK, PH);</li>\n      <li>Tonafil (TH);</li>\n      <li>Topgra (ID);</li>\n      <li>V-Gra (BD);</li>\n      <li>Varonil (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Vasigra (LK);</li>\n      <li>Viagra (AE, AT, AU, BB, BE, BF, BH, BJ, BR, CH, CI, CL, CN, CO, CR, CY, CZ, DE, DK, DO, EC, EE, EG, ES, ET, FI, FR, GB, GH, GM, GN, GR, GT, HK, HN, HR, HU, ID, IE, IL, IQ, IR, IS, IT, JO, JP, KE, KR, KW, LB, LK, LR, LT, LU, LV, LY, MA, ML, MR, MT, MU, MW, MX, MY, NE, NG, NI, NL, NZ, OM, PA, PE, PH, PL, PT, QA, RO, RU, SA, SC, SD, SE, SG, SI, SK, SL, SN, SV, SY, TH, TN, TR, TW, TZ, UG, UY, VE, VN, YE, ZA, ZM, ZW);</li>\n      <li>Viahra (UA);</li>\n      <li>Viajoy (ID);</li>\n      <li>Viasin Powder (KR);</li>\n      <li>Viner (HR);</li>\n      <li>Vivic (HK, MY);</li>\n      <li>Vizarsin (IE, MT, PL);</li>\n      <li>Willmon-100 (HK);</li>\n      <li>Wingora (PH);</li>\n      <li>X-cite (BD);</li>\n      <li>Xcite (LK);</li>\n      <li>Xex (EC);</li>\n      <li>Zilden (PH);</li>\n      <li>Zwagra (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. <i>J Pediatr</i>. 2001;139(2):317-319.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sildenafil-drug-information/abstract-text/11487763/pubmed\" target=\"_blank\" id=\"11487763\">11487763</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Anderson JL, Adams CD, Antman EM, et al; American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. 2012 ACCF/AHA focused update incorporated into the ACCF/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. <i>Circulation</i>. 2013;127(23):e663-e828. doi: 10.1161/CIR.0b013e31828478ac.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sildenafil-drug-information/abstract-text/23630129/pubmed\" target=\"_blank\" id=\"23630129\">23630129</a>]</span><span class=\"doi\">10.1161/CIR.0b013e31828478ac</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"26043796\"></a>Baker WL, Radojevic J, Gluck JA. Systematic review of phosphodiesterase-5 inhibitor use in right ventricular failure following left ventricular assist device implantation. <i>Artif Organs</i>. 2016;40(2):123-128.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sildenafil-drug-information/abstract-text/26043796/pubmed\" target=\"_blank\" id=\"26043796\">26043796</a>]</span><span class=\"doi\">10.1161/CIR.0b013e31828478ac</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Barst RJ, Ivy DD, Gaitan G, et al, &ldquo;A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of Oral Sildenafil Citrate in Treatment-Na&iuml;ve Children With Pulmonary Arterial Hypertension,&rdquo; <i>Circulation</i>, 2012a, 125(2):324-34.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sildenafil-drug-information/abstract-text/22128226/pubmed\" target=\"_blank\" id=\"22128226\">22128226</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Barst RJ, Layton GR, Konourina I, et al. STARTS-2: long-term survival with oral sildenafil monotherapy in treatment-na&iuml;ve patients with pediatric pulmonary arterial hypertension. <i>Eur Heart Jour</i>. 2012. 33:979.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sildenafil-drug-information/abstract-text/24637559/pubmed\" target=\"_blank\" id=\"24637559\">24637559</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Behling A, Rohde LE, Colombo FC, et al, &quot;Effects of 5'-Phosphodiesterase Four-Week Long Inhibition With Sildenafil in Patients With Chronic Heart Failure: A Double-Blind, Placebo-Controlled Clinical Trial,&quot; <i>J Card Fail</i>, 2008, 14(3):189-97<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sildenafil-drug-information/abstract-text/18381181/pubmed\" target=\"_blank\" id=\"18381181\">18381181</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Blanco I, Gimeno E, Munoz PA, et al, &quot;Hemodynamic and Gas Exchange Effects of Sildenafil in Patients With Chronic Obstructive Pulmonary Disease and Pulmonary Hypertension,&quot; <i>Am J Respir Crit Care Med</i>, 2010, 181(3):270-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sildenafil-drug-information/abstract-text/19875684/pubmed\" target=\"_blank\" id=\"19875684\">19875684</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cartago RS, Alan PA, Benedicto J. Pregnancy outcomes in patients with severe pulmonary hypertension and Eisenmenger syndrome treated with sildenafil monotherapy. <i>Obstet Med</i>. 2014;7(1):40-42. doi: 10.1177/1753495X13514403.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sildenafil-drug-information/abstract-text/27512419/pubmed\" target=\"_blank\" id=\"27512419\">27512419</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol&mdash;United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291. <a href=\"http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm\" target=\"_blank\">http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm</a><span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sildenafil-drug-information/abstract-text/6810084/pubmed\" target=\"_blank\" id=\"6810084\">6810084</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cheitlin MD, Hutter AM Jr, Brindis RG, et al, &ldquo;Use of Sildenafil (Viagra&reg;) in Patients With Cardiovascular Disease,&rdquo; <i>J Am Coll Cardiol</i>, 1999, 33(1):273-82.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sildenafil-drug-information/abstract-text/9935041/pubmed\" target=\"_blank\" id=\"9935041\">9935041</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"17356110\"></a>Collard HR, Anstrom KJ, Schwarz MI, Zisman DA. Sildenafil improves walk distance in idiopathic pulmonary fibrosis. <i>Chest</i>. 2007;131(3):897-899.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sildenafil-drug-information/abstract-text/17356110/pubmed\" target=\"_blank\" id=\"17356110\">17356110</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"27926905\"></a>Dunn L, Greer R, Flenady V, Kumar S. Sildenafil in pregnancy: a systematic review of maternal tolerance and obstetric and perinatal outcomes. <i>Fetal Diagn Ther</i>. 2017;41(2):81-88. doi: 10.1159/000453062.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"26767411\"></a>Dunn L, Flenady V, Kumar S. Reducing the risk of fetal distress with sildenafil study (RIDSTRESS): a double-blind randomised control trial. <i>J Transl Med</i>. 2016;14:15. doi: 10.1186/s12967-016-0769-0.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"23352391\"></a>Feldman D, Pamboukian SV, Teuteberg JJ, et al. The 2013 International Society for Heart and Lung Transplantation Guidelines for mechanical circulatory support: executive summary. <i>J Heart Lung Transplant</i>. 2013;32(2):157-187.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sildenafil-drug-information/abstract-text/23352391/pubmed\" target=\"_blank\" id=\"23352391\">23352391</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fries R, Shariat K, von Wilmowsky H, B&ouml;hm M. Sildenafil in the treatment of Raynaud's phenomenon resistant to vasodilatory therapy. <i>Circulation</i>. 2005;112:2980-2985.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sildenafil-drug-information/abstract-text/16275885/pubmed\" target=\"_blank\" id=\"16275885\">16275885</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gali&egrave; N, Corris PA, Frost A, et al. Updated treatment algorithm of pulmonary arterial hypertension. <i>J Am Coll Cardiol</i>. 2013;62(25 Suppl):D60-D72. doi: 10.1016/j.jacc.2013.10.031.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sildenafil-drug-information/abstract-text/24355643/pubmed\" target=\"_blank\" id=\"24355643\">24355643</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gali&egrave; N, Ghofrani HA, Torbicki A, et al; Sildenafil Use in Pulmonary Arterial Hypertension (SUPER) Study Group. Sildenafil citrate therapy for pulmonary arterial hypertension [published correction appears in <i>N Engl J Med</i>. 2006;354(22):2400-2401]. <i>N Engl J Med</i>. 2005;353(20):2148-2157.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sildenafil-drug-information/abstract-text/16291984/pubmed\" target=\"_blank\" id=\"16291984\">16291984</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"24689700\"></a>Hamdan R, Mansour H, Nassar P, Saab M. Prevention of right heart failure after left ventricular assist device implantation by phosphodiesterase 5 inhibitor. <i>Artif Organs</i>. 2014;38(11):963-967.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sildenafil-drug-information/abstract-text/24689700/pubmed\" target=\"_blank\" id=\"24689700\">24689700</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hsu CH, Gomberg-Maitland M, Glassner C, et al, &quot;The Management of Pregnancy and Pregnancy-Related Medical Conditions in Pulmonary Arterial Hypertension Patients,&quot; <i>Int J Clin Pract Suppl</i>, 2011,172:6-14.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sildenafil-drug-information/abstract-text/21736676/pubmed\" target=\"_blank\" id=\"21736676\">21736676</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    &quot;Inactive&quot; ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics (AAP) Committee on Drugs. <i>Pediatrics</i>. 1997;99(2):268-278.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sildenafil-drug-information/abstract-text/9024461/pubmed\" target=\"_blank\" id=\"9024461\">9024461</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Jackson G and Chambers J, &ldquo;Sildenafil for Primary Pulmonary Hypertension: Short and Long-Term Symptomatic Benefit,&rdquo; <i>Int J Clin Pract</i>, 2002 56(5):397-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sildenafil-drug-information/abstract-text/12137450/pubmed\" target=\"_blank\" id=\"12137450\">12137450</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Jackson G, Rosen RC, Kloner RA, et al, &ldquo;The Second Princeton Consensus on Sexual Dysfunction and Cardiac Risk: New Guidelines for Sexual Medicine,&rdquo; <i>J Sex Med</i>, 2006, 3(1):28-36.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sildenafil-drug-information/abstract-text/16409215/pubmed\" target=\"_blank\" id=\"16409215\">16409215</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Karatza AA, Bush A, and Magee AG, &ldquo;Safety and Efficacy of Sildenafil Therapy in Children With Pulmonary Hypertension,&rdquo; <i>Int J Cardiol</i>, 2005, 100(2):267-73.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Karatza AA, Narang I, Rosenthal M, et al, &ldquo;Treatment of Primary Pulmonary Hypertension With Oral Sildenafil,&rdquo; <i>Respiration</i>, 2004, 71(2):192-4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sildenafil-drug-information/abstract-text/15031578/pubmed\" target=\"_blank\" id=\"15031578\">15031578</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Keogh AM, Jabbour A, Hayward CS, et al, &ldquo;Clinical Deterioration After Sildenafil Cessation In Patients With Pulmonary Hypertension,&rdquo; <i>Vasc Health Risk Manag</i>, 2008, 4(5):1111-3.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sildenafil-drug-information/abstract-text/19183760/pubmed\" target=\"_blank\" id=\"19183760\">19183760</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"17184632\"></a>Klodell CT Jr, Morey TE, Lobato EB, et al. Effect of sildenafil on pulmonary artery pressure, systemic pressure, and nitric oxide utilization in patients with left ventricular assist devices. <i>Ann Thorac Surg</i>. 2007;83(1):68-71.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sildenafil-drug-information/abstract-text/17184632/pubmed\" target=\"_blank\" id=\"17184632\">17184632</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Li WQ, Qureshi AA, Robinson KC, Han J. Sildenafil use and increased risk of incident melanoma in US men: a prospective cohort study. <i>JAMA Intern Med</i>. 2014;174(6):964-970.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sildenafil-drug-information/abstract-text/24710960/pubmed\" target=\"_blank\" id=\"24710960\">24710960</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Loeb S, Folkvaljon Y, Lambe M, et al. Use of Phosphodiesterase Type 5 Inhibitors for Erectile Dysfunction and Risk of Malignant Melanoma. <i>JAMA</i>. 2015;313(24):2449-2455.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sildenafil-drug-information/abstract-text/26103029/pubmed\" target=\"_blank\" id=\"26103029\">26103029</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"16574495\"></a>Madden BP, Allenby M, Loke TK, Sheth A. A potential role for sildenafil in the management of pulmonary hypertension in patients with parenchymal lung disease. <i>Vascul Pharmacol</i>. 2006;44(5):372-376.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sildenafil-drug-information/abstract-text/16574495/pubmed\" target=\"_blank\" id=\"16574495\">16574495</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    McLaughlin VV, Archer SL, Badesch DB, et al, &ldquo;ACCF/AHA 2009 Expert Consensus Document on Pulmonary Hypertension. A Report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association Developed in Collaboration With the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association,&rdquo; <i>J Am Coll Cardiol</i>, 2009, 53(17):1573-619.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sildenafil-drug-information/abstract-text/19389575/pubmed\" target=\"_blank\" id=\"19389575\">19389575</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    McVary KT, &ldquo;Clinical Practice. Erectile Dysfunction,&rdquo; <i>N Engl J Med</i>, 2007, 357(24):2472-81.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sildenafil-drug-information/abstract-text/18077811/pubmed\" target=\"_blank\" id=\"18077811\">18077811</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mukherjee A, Dombi T, Wittke B, et al, &quot;Population Pharmacokinetics of Sildenafil in Term Neonates: Evidence of Rapid Maturation of Metabolic Clearance in the Early Postnatal Period,&quot; <i>Clin Pharmacol Ther</i>, 2009, 85(1):56-63.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sildenafil-drug-information/abstract-text/18800037/pubmed\" target=\"_blank\" id=\"18800037\">18800037</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"11377161\"></a>Mychaskiw G, Sachdev V, Heath BJ. Sildenafil (Viagra) facilitates weaning of inhaled nitric oxide following placement of a biventricular-assist device. <i>J Clin Anesth</i>. 2001;13(3):218-220.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sildenafil-drug-information/abstract-text/11377161/pubmed\" target=\"_blank\" id=\"11377161\">11377161</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nehra A, Jackson G, Miner M, et al. The Princeton III Consensus recommendations for the management of erectile dysfunction and cardiovascular disease. Mayo Clin Proc. 2012;87(8):766-778. doi: 10.1016/j.mayocp.2012.06.015.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sildenafil-drug-information/abstract-text/22862865/pubmed\" target=\"_blank\" id=\"22862865\">22862865</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"23247304\"></a>O'Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines [published correction appears in <i>Circulation</i>. 2013;128(25):e481.] <i>Circulation</i>. 2013;127(4):e362-e425.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sildenafil-drug-information/abstract-text/23247304/pubmed\" target=\"_blank\" id=\"23247304\">23247304</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"29282009\"></a>Pels A, Kenny LC, Alfirevic Z, et al; international STRIDER Consortium. STRIDER (Sildenafil Therapy in dismal prognosis early onset fetal growth restriction): an international consortium of randomised placebo-controlled trials. <i>BMC Pregnancy Childbirth</i>. 2017;17(1):440. doi: 10.1186/s12884-017-1594-z.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Phillips BG, Kato M, Pesek CA, et al, &ldquo;Sympathetic Activation by Sildenafil,&rdquo; <i>Circulation</i>, 2000, 102(25):3068-73.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sildenafil-drug-information/abstract-text/11120696/pubmed\" target=\"_blank\" id=\"11120696\">11120696</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Prasad S, Wilkinson J, and Gatzoulis MA, &ldquo;Sildenafil in Primary Pulmonary Hypertension,&rdquo; <i>N Engl J Med</i>, 2000, 343(18):1342.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sildenafil-drug-information/abstract-text/11183578/pubmed\" target=\"_blank\" id=\"11183578\">11183578</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Revatio (sildenafil citrate) [prescribing information]. New York, NY: Pfizer Labs; February 2018.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Revatio (sildenafil citrate) [product monograph]. Kirkland, Quebec, Canada: Pfizer Canada Inc; October 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Roustit M, Blaise S, Allanore Y, Carpentier PH, Caglayan E, Cracowski JL. Phosphodiesterase-5 inhibitors for the treatment of secondary Raynaud's phenomenon: systematic review and meta-analysis of randomised trials. <i>Ann Rheum Dis</i>. 2013;72:1696-1699.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sildenafil-drug-information/abstract-text/23426043/pubmed\" target=\"_blank\" id=\"23426043\">23426043</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Simonneau G, Rubin LJ, Gali&egrave; N, et al, &ldquo;Addition of Sildenafil to Long-Term Intravenous Epoprostenol Therapy in Patients With Pulmonary Arterial Hypertension: A Randomized Trial,&rdquo; <i>Ann Intern Med</i>, 2008, 149(8):521-30.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sildenafil-drug-information/abstract-text/18936500/pubmed\" target=\"_blank\" id=\"18936500\">18936500</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Taichman DB, Ornelas J, Chung L, et al. Pharmacologic therapy for pulmonary arterial hypertension in adults: CHEST guideline and expert panel report. <i>Chest</i>. 2014;146(2):449-475. doi: 10.1378/chest.14-0793.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sildenafil-drug-information/abstract-text/24937180/pubmed\" target=\"_blank\" id=\"24937180\">24937180</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"19808294\"></a>Tedford RJ, Hemnes AR, Russell SD, et al, &quot;PDE5A Inhibitor Treatment of Persistent Pulmonary Hypertension After Mechanical Circulatory Support,&quot; <i>Circ Heart Fail</i>, 2008, 1(4):213-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sildenafil-drug-information/abstract-text/19808294/pubmed\" target=\"_blank\" id=\"19808294\">19808294</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Toshner MR, Gopalan D, Suntharalingam J, et al, &quot;Pulmonary Arterial Size and Response to Sildenafil in Chronic Thromboembolic Pulmonary Hypertension,&quot; <i>J Heart Lung Transplant</i>, 2010, 29(6):610-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sildenafil-drug-information/abstract-text/20227301/pubmed\" target=\"_blank\" id=\"20227301\">20227301</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Viagra (sildenafil citrate) [prescribing information]. New York, NY: Pfizer Labs; December 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Viagra (sildenafil citrate) [product monograph]. Kirkland, Quebec, Canada: Pfizer Canada Inc; May 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wollein U, Schech B, Hardt J, Schramek N. Determination and quantitation of sildenafil and its major metabolite in the breast milk of a lactating woman. <i>J Pharm Biomed Anal</i>. 2016;120:100-105. doi: 10.1016/j.jpba.2015.12.006.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sildenafil-drug-information/abstract-text/26717019/pubmed\" target=\"_blank\" id=\"26717019\">26717019</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9643 Version 228.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F220995\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F220996\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F221028\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F221000\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F221001\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F221002\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F221003\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F220969\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F220955\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F220971\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F220970\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25744905\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F221036\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F220962\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F220974\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F220959\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F221022\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F220964\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F220991\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F220978\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F16571140\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Dietary Considerations\" href=\"#F9614168\" class=\"outlineLink\">Dietary Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F14971852\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F220958\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F220973\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F220977\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F220980\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9643|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=sildenafil-patient-drug-information\" class=\"drug drug_patient\">Sildenafil: Patient drug information</a></li><li><a href=\"topic.htm?path=sildenafil-pediatric-drug-information\" class=\"drug drug_pediatric\">Sildenafil: Pediatric drug information</a></li></ul></div></div>","javascript":null}